Tacrolimus
- Generic Name
- Tacrolimus
- Brand Names
- Advagraf, Astagraf, Envarsus, Modigraf, Prograf, Protopic, Tacforius
- Drug Type
- Small Molecule
- Chemical Formula
- C44H69NO12
- CAS Number
- 104987-11-3
- Unique Ingredient Identifier
- Y5L2157C4J
- Background
Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condi...
- Indication
Immediate-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, heart, or lung transplants, in combination with other immunosuppressants. Extended-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric ...
- Associated Conditions
- Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Oral Lichen Planus, Psoriasis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Atopic Dermatitis, Vitiligo, Moderate Atopic dermatitis
- Associated Therapies
- -
Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus
- Conditions
- Interventions
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Chinese SLE Treatment And Research Group
- Target Recruit Count
- 220
- Registration Number
- NCT05916781
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
Allogeneic Hematopoietic Stem Cell Transplantation With JSP191-Based Conditioning in Participants With GATA2 Deficiency
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT05907746
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Heinrich-Heine University, Duesseldorf
- Target Recruit Count
- 38
- Registration Number
- NCT05807932
- Locations
- 🇩🇪
Universitätsklinikum Frankfurt Medizinische Klinik II, Frankfurt, Germany
🇩🇪Universitätsklinikum Jena - Klinik für Innere Medizin II, Jena, Germany
🇩🇪Universitätsklinikum Aachen - Med. Klinik IV, Aachen, NRW, Germany
Assessment of the Pharmacokinetic Profile of Tacrolimus Medications and Their Relation to Effectiveness and Safety in Liver Transplant Patients
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Chiesi Hungary Ltd.
- Target Recruit Count
- 110
- Registration Number
- NCT05744635
- Locations
- 🇭🇺
Semmelweis University, Department of Surgery, Transplantation and Gastroenterology, Budapest, Hungary
🇸🇮University Medical Center Ljubljana, Division of Internal Medicine, Department of Gastroenterology, Ljubljana, Slovenia
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT05736419
- Locations
- 🇺🇸
Memorial Sloan Kettering Bergen (Consent only), Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Consent only), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering at Basking Ridge (Consent only), Basking Ridge, New Jersey, United States
A Study to Evaluate the Safety and Efficacy of Zanubrutinib in Participants With Primary Membranous Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2023-01-31
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 282
- Registration Number
- NCT05707377
- Locations
- 🇺🇸
Carolina Nephrology, Spartanburg, South Carolina, United States
🇺🇸Prolato Clinical Research Center, Houston, Texas, United States
🇨🇳Zhejiang Provincial Peoples Hospital, Hangzhou, Zhejiang, China
Tacrolimus Plus Glucocorticoid for Severe Thrombocytopenia in SS
- Conditions
- Interventions
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2023-01-23
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 110
- Registration Number
- NCT05694130
Tacrolimus for Thrombocytopenia in SS
- Conditions
- Interventions
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 54
- Registration Number
- NCT05678335
Prognostic Model of TAC in the Treatment of MN
- First Posted Date
- 2022-12-29
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Qianfoshan Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT05667922
Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Fen Li
- Target Recruit Count
- 30
- Registration Number
- NCT05666336
- Locations
- 🇨🇳
Department of Rheumatology and Immunology, Xiangya Second Hospital, Central South University, Changsha, Hunan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.